CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Isotretinoindrug
Likely dose
Isotretinoin 1.5 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04594759
NCT04594759Phase 2Completed
CompareCT.gov

Weekly Isotretinoin Therapy for the Treatment of Moderate Acne Vulgaris

Medical University of South Carolina·interventional·Posted Oct 20, 2020·Updated May 9, 2022

In Brief

A Phase 2 clinical trial evaluating Isotretinoin for Acne Vulgaris. Completed, enrolled 22 participants across 1 site.

Detailed Summary

In current Dermatology practice, options for moderate acne vulgaris remain limited. The mainstay of treatment for moderate acne remains long courses of oral antibiotics despite emerging antibiotic resistance. The efficacy of daily to twice daily dosed isotretinoin, an oral vitamin A derivative, for treatment of severe acne has been well established. The purpose of this study is to determine if once weekly dosed isotretinoin is effective for the treatment of patients with moderate acne. Additionally, the study aims to evaluate patient satisfaction and identify any adverse effects on this alternative dosing regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedOct 20, 2020
Enrollment StartNov 11, 2020
Primary CompletionDec 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.7 years ago

Interventions

Isotretinoindrug

Participants will be getting isotretinoin (1-1.5 mg/kg/week)